https://www.hodgkinlymphom.de/lunsumio-und-polivy-erhalten-fda-zulassung-fuer-grosszelliges-b-zell-lymphom/
Lunsumio und Polivy erhalten FDA-Zulassung für großzelliges B-Zell-Lymphom - Hodgkin Lymphom Forum
Jun 28, 2026 - Roche hat in den USA die FDA-Zulassung für die Kombination aus Lunsumio (Mosunetuzumab) und Polivy (Polatuzumab vedotin) für großzelliges B-Zell-Lymphom...
lunsumioundpolivyerhaltenfda
https://hillman.upmc.com/patients/community-support/education/chemotherapy-drugs/polatuzumab
Polatuzumab vedotin-piiq (Polivy) | UPMC Hillman Cancer Center
Polatuzumab vedotin-piiq (Polivy) is given by vein (IV) to treat cancer. Find side effects, allergic reactions, and food and drug interactions.
hillman cancer centerpolatuzumab vedotinpolivyupmc